NASDAQ:NMAD Lixte Biotechnology Q1 2026 Earnings Report $3.58 -0.05 (-1.38%) As of 09/25/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Lixte Biotechnology EPS ResultsActual EPS-$0.18Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALixte Biotechnology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALixte Biotechnology Announcement DetailsQuarterQ1 2026Date5/14/2026TimeAfter Market ClosesConference Call DateThursday, May 14, 2026Conference Call Time8:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Lixte Biotechnology Earnings HeadlinesNOMAD Power Solutions Expands Its Canadian Commercial Presence with Appointment of Global Environmental Liquid Ltd. as Sales RepresentativeSeptember 25 at 8:30 AM | globenewswire.comNOMAD Power Solutions, Inc.: Nomad Power Solutions Files Expanded Business And Financial Disclosure Following Completion Of MergerSeptember 18, 2026 | finanznachrichten.deThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)NOMAD POWER SOLUTIONS FILES EXPANDED BUSINESS AND FINANCIAL DISCLOSURE FOLLOWING COMPLETION OF MERGERSeptember 17, 2026 | globenewswire.comNomad Power Solutions Inc NMADSeptember 16, 2026 | morningstar.comMRented Fleets Are Winning the Infrastructure Buildout as Mega Projects MultiplySeptember 11, 2026 | prnewswire.comSee More Lixte Biotechnology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lixte Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lixte Biotechnology and other key companies, straight to your email. Email Address About Lixte BiotechnologyLixte Biotechnology (NASDAQ:NMAD) is a clinical-stage biotechnology company focused on developing cancer therapies that target protein phosphatase 2A (PP2A), an enzyme involved in regulating cell growth, survival and response to treatment. The company’s research is based on the premise that inhibiting PP2A may help make cancer cells more vulnerable to existing therapies. Lixte’s lead investigational compound is LB-100, a small-molecule PP2A inhibitor being evaluated in combination with other cancer treatments. The company has explored LB-100 in preclinical studies and early-stage clinical trials involving solid tumors and other malignancies. Lixte’s development strategy centers on combining its PP2A-targeting compounds with chemotherapy, radiation, immunotherapy or other targeted treatments. Founded in 2001, Lixte is headquartered in Pasadena, California. As a clinical-stage company, it focuses primarily on research and development and does not have an established commercial product portfolio. Its programs are directed toward potential applications in oncology, although the safety and effectiveness of its investigational treatments remain subject to clinical testing and regulatory review.View Lixte Biotechnology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
